retinoic acid and arsenic for treating acute promyelocytic leukemia维甲酸治疗急性早幼粒细胞白血病和砷.pdfVIP

Open access, freely available online Research in Translation Retinoic Acid and Arsenic for Treating Acute Promyelocytic Leukemia Guang-Biao Zhou, Wei-Li Zhao, Zhen-Yi Wang, Sai-Juan Chen, Zhu Chen* cute promyelocytic leukemia An important discovery of the early [12]. Morphological maturation of (APL) was fi rst identifi ed as 1970s was that myeloid leukemic cells bone marrow cells was found in all Aa distinct subtype of acute could be reprogrammed to resume patients studied. myeloid leukemia in 1957 by Leif normal differentiation and to become These results were later confi rmed Hillestad. It is called M3 in the non-dividing mature granulocytes or by many randomized studies in centers French–American–British classifi cation, macrophages as a result of stimulation around the world. Further trials showed with a variant type referred to as by various cytokines [3,4]. Based on this improved rates of CR, a decrease in microgranular (M3v in the French– discovery, Leo Sachs at the Weizmann severe adverse effects, and lengthening American–British nomenclature) [1]. Institute of Science, Rehovot, Israel, of the duration of remission. Table 1 APL is characterized by three features: hypothesized in 1978 that treatment summarizes the CR rates obtained in (1) the presence of an accumulation with agents that induce cancer cells most large series of patients. Currently, of abnormal promyelocytes (see